MAPLE GROVE, Minn., Nov. 26, 2012 /PRNewswire/ --Upsher-Smith Laboratories, Inc. (Upsher-Smith) a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, is proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 December 4, 2012.
"Upsher-Smith is committed to working toward improving the lives of people living with epilepsy," said Pamela J. Davis, M.D., Sr. Director Medical Affairs, Medical Strategy, Upsher-Smith. "USL261 (midazolam) is being developed for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters. This is a condition where few treatment options presently exist, particularly for the outpatient setting."
USL261 (midazolam) is a benzodiazepine in an investigational formulation that is delivered intranasally. It is intended to be administered by a caregiver in an outpatient setting for the rescue treatment of seizure clusters without active inhalation by the patient.
Upsher-Smith plans to sponsor presentations for three investigational drug programs in epilepsy at the AES annual meeting. Following is a guide to Upsher-Smith-sponsored presentations during the meeting. To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.
Upsher-Smith-Sponsored Posters
1. Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration, in Subjects with Epilepsy Poster 1.366; Poster Session 1, Saturday, December 1, 2012, 11:45 a.m. - 6:00 p.m. (Pacific Time); Authors Present 11:45 a.m. - 1:45 p.m.
2. Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam Optimized for Intranasal Administration, in Subjects with Epilepsy Poster 1.373; Poster Session 1, Saturday, December 1, 2012, 11:45 a.m. - 6:00 p.m. (Pacific Time); Authors Present 11:45 a.m. - 1:45 p.m.
3. Safety and Pharmacodynamics of USL261, a Novel Formulation of Intranasal Midazolam Poster Session 3.239; Poster Session 3; Monday, December 3, 2012, 8:00 a.m. - 3:00 p.m. (Pacific Time); Authors Present 12:00 p.m. - 2:00 p.m.
4.Pharmacokinetics of USL261, A Novel Formulation of Intranasal Midazolam Poster Session 3.238; Poster Session 3; Monday, December 3, 2012, 8:00 a.m. - 3:00 p.m. (Pacific Time); Authors Present 12:00 p.m. - 2:00 p.m.
5.Establishing Maximum Tolerated Dose and Dose-Proportionality in Extended-Release Topiramate (USL255) Poster Session 3.233; Poster Session 3; Monday, December 3, 2012, 8:00 a.m. - 3:00 p.m. (Pacific Time); Authors Present 12:00 p.m. - 2:00 p.m.
See the original post:
Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy ...